Abbott/TAP joint venture readjusts 2004 sales expectations due to a reported 7% year-to-date decline in the Rx PPI market. Prilosec OTC has "probably had more of an impact on the branded side than anticipated, or at least the impact has lasted longer," says Abbott Divisional VP-Investor Relations John Thomas in a July 9 earnings call. TAP now expects full-year Prevacid sales to decrease by around 10%, according to Abbott, and will attempt to reinvigorate the brand by targeting adolescents and launching new formulations such as the recently approved Prevacid SoluTab Orally Disintegrating Tablets. SoluTabs provide "flexibility and convenience, especially in children and other patients that have difficulty swallowing," states Abbott VP-Investor Relations & Public Affairs Catherine Babington. The firm expects the branded PPI market will grow "at a more modest rate" in the second half of 2004...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
